Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
it
en
15 March 2024 |
Explanatory memorandum to amend total fixed annual remuneration of the BoD
